Press Releases

August 12, 2013
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Acute Myelogenous Leukemia

August 08, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613 for the Treatment of Advanced Bile Duct Cancers

June 03, 2013
Cornerstone Pharmaceuticals Presents Data at 2013 Annual ASCO Meeting

May 23, 2013
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 in Patients with Advanced Solid Tumors

April 30, 2013
Cornerstone Pharmaceuticals Appoints Dr. Sim Fass and Howard Jonas to Board of Directors

April 22, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613 with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer

September 28, 2012
Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at the Tenth Annual Discovery On Target Conference in Boston regarding cancer cell metabolism

September 24, 2012
Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at BioX 2012 Conference

June 01, 2012
Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613 at 2012 Annual ASCO Meeting

April 30, 2012
Cornerstone Pharmaceuticals announces publication of case report on treatment of a patient presenting metastatic pancreatic cancer with CPI-613 and gemcitabine combination therapy